If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 31 - 40 of 294
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors
To assess the safety, tolerability, dose-limiting toxicities (DLTs), and determine the maximum tolerated dose of INBRX-106 as a single agent administered as an intravenous infusion and in combination with pembrolizumab.
Protocol No
INHIBRX-PH1-INBRX-106
A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer
Trastuzumab in Patients with Unresectable Her2-Positive Salivary Gland Cancer
Protocol No
NRG-HN010
Categories
Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
Testing a narrower margin in surgery for patients with primary cutaneous melanoma
We are doing this study because we want to find out if this approach is better or worse than the usual approach for melanoma surgery. The usual approach is defined as care most people get for melanoma.
We are doing this study because we want to find out if this approach is better or worse than the usual approach for melanoma surgery. The usual approach is defined as care most people get for melanoma.
Protocol No
SWOG-S2015
Categories
A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy with or without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer (NRG PROMETHEAN)
Protocol No
NRG-GU011-PROMETHEAN
Categories
A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)
This project is being done to see how safe and how well the study drug asciminib works
for participants with CML-CP who have had one prior therapy
for participants with CML-CP who have had one prior therapy
Protocol No
NOVARTIS-CABL001AUS08
Categories
A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults with Relapsed and/or Refractory Solid Tumor Malignancies
Study to Assess the Safety of LYL797, ROR1-Targeting CAR T Cells, in Adults with R/R solid tumor
Protocol No
LYELL-LYL-797-101
Categories
A Phase 1b/2 Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
A Phase 1b/2 Study to Evaluate TTI-101 in Participants with HCC
Protocol No
TVARDI-TVD-101-001H
Categories
Phase IIA Single-Arm Study of Treatment of Patients with Advanced Liver Cancer with a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody
Combination of TATE and PD-1 Inhibitor in Liver Cancer (TATE-PD1)
Protocol No
TECLISON-LT-004-TATE-PD1
Categories
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
A Phase 1/2 Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Protocol No
MIRATI-1719-001
Categories
Cancer,
Colorectal,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Breast Cancers,
Lung,
Esophagus,
Other Skin,
Melanoma, Skin,
Other Urologic,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Other Gynecologic,
Uterine,
Ovary,
Cervix,
Other Gastrointestinal,
Stomach,
Pancreas/Liver,
Esophagus
Inhibition of Oral Tumorigenesis by Antitumor B
IIT-WONG-ATB-RANDOMIZED
Protocol No
IIT-WONG-ATB-RANDOMIZED
Categories